Conduct study P210
Ended Awarded Last action
- Contract number
- 75N93019F00131
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $890,036
Award facts
- Opportunity
-
- NIAIDDAIDSNIHAI2012138 Solicitation number
- Contract value 100% obligated
- $890,036.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $11,916 | |
| Funding Only Action | -$5,111 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $883,231 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for the "CONDUCT STUDY P210" project. The contract has a ceiling value of $890,036.10 and an ultimate completion date of April 30, 2022. This award is part of the larger Simian Vaccine Evaluation Units 2013-2020 master IDIQ contract, under which ABL has been providing a range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies. The contract does not have a set-aside designation, as ABL is a large, foreign-owned, for-profit manufacturer of goods. Through this and other federal contract vehicles, ABL has contributed to various infectious disease countermeasure programs, including work on HIV, influenza, and other vaccines and therapeutics.
Quick answers
Who was awarded contract 75N93019F00131?
75N93019F00131 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 20, 2019.
How much is contract 75N93019F00131 worth?
The government has obligated $890,036 on 75N93019F00131.
Is contract 75N93019F00131 an order under another contract?
Yes. 75N93019F00131 is a delivery order under HHSN272201300002I, an indefinite delivery contract, on Simian Vaccine Evaluation Units 2013-2020.
Was contract 75N93019F00131 competed?
The extent of competition for 75N93019F00131 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award